nach oben

Erschienen in:

19.09.2019 | Review articles

Cardiac abnormalities in patients with nonalcoholic fatty liver disease

Insights from auxiliary examinations

verfasst von: Yu Dong, MD, Guangsen Li, PhD

Erschienen in: Herz | Ausgabe 2/2021

Einloggen, um Zugang zu erhalten

Abstract

Nonalcoholic fatty liver disease (NAFLD) is one of the most common forms of chronic liver disease in developed countries and is associated with type 2 diabetes mellitus, obesity, hypertension, dyslipidemia, and metabolic syndrome. It is defined as steatosis in over 5% of hepatocytes. The disease spectrum of NAFLD ranges from simple fatty liver to nonalcoholic steatohepatitis, liver fibrosis, even hepatic cirrhosis. The disease affects various extra-hepatic systems such as the cardiovascular system and urinary system. Heart-related disease is identified as the leading cause of mortality in NAFLD patients rather than liver-related disease. In this review, we summarize the cardiac abnormalities (structural, functional, arrhythmic cardiac complications etc.) seen in NAFLD patients with the assistance of auxiliary examinations, such as electrocardiography, echocardiography, computed tomography, magnetic resonance imaging etc. In addition, the epidemiology of NAFLD and how NAFLD affects the myocardium are also discussed.

European Association for the Study of the Liver (EASL), European Association for the Study of Diabetes (EASD), European Association for the Study of Obesity (EASO). (2016) EASL-EASD-EASO Clinical Practice Guidelines for the management of non-alcoholic fatty liver disease. J Hepatol 64(6):1388–1402. https://doi.org/10.1016/j.jhep.2015.11.004CrossRef

Younossi ZM, Koenig AB, Abdelatif D, Fazel Y, Henry L, Wymer M (2016) Global epidemiology of nonalcoholic fatty liver disease-meta-analytic assessment of prevalence, incidence, and outcomes. Hepatology 64(1):73–84. https://doi.org/10.1002/hep.28431CrossRefPubMed

Fargion S, Porzio M, Fracanzani AL (2014) Nonalcoholic fatty liver disease and vascular disease: state-of-the-art. World J Gastroenterol 20(37):13306–13324. https://doi.org/10.3748/wjg.v20.i37.13306CrossRefPubMedPubMedCentral

de Alwis NM, Day CP (2008) Non-alcoholic fatty liver disease: the mist gradually clears. J Hepatol 48(Suppl 1):S104–S112. https://doi.org/10.1016/j.jhep.2008.01.009CrossRefPubMed

Perseghin G, Lattuada G, De Cobelli F, Esposito A, Belloni E, Ntali G, Ragogna F, Canu T, Scifo P, Del Maschio A, Luzi L (2008) Increased mediastinal fat and impaired left ventricular energy metabolism in young men with newly found fatty liver. Hepatology 47(1):51–58. https://doi.org/10.1002/hep.21983CrossRefPubMed

Lonardo A, Bellentani S, Argo CK, Ballestri S, Byrne CD, Caldwell SH, Cortez-Pinto H, Grieco A, Machado MV, Miele L, Targher G (2015) Epidemiological modifiers of non-alcoholic fatty liver disease: focus on high-risk groups. Dig Liver Dis 47(12):997–1006. https://doi.org/10.1016/j.dld.2015.08.004CrossRefPubMed

Loomba R, Sanyal AJ (2013) The global NAFLD epidemic. Nat Rev Gastroenterol Hepatol 10(11):686–690. https://doi.org/10.1038/nrgastro.2013.171CrossRefPubMed

Fan JG, Jia JD, Li YM, Wang BY, Lu LG, Shi JP, Chan LY (2011) Guidelines for the diagnosis and management of nonalcoholic fatty liver disease: update 2010. J Dig Dis 12(1):38–44. https://doi.org/10.1111/j.1751-2980.2010.00476.x (published in Chinese on Chinese Journal of Hepatology 2010; 18:163–166)CrossRefPubMed

Farrell GC, Wong VW, Chitturi S (2013) NAFLD in Asia—as common and important as in the West. Nat Rev Gastroenterol Hepatol 10(5):307–318. https://doi.org/10.1038/nrgastro.2013.34CrossRefPubMed

10.

Singh SP, Nayak S, Swain M, Rout N, Mallik RN, Agrawal O, Meher C, Rao M (2004) Prevalence of nonalcoholic fatty liver disease in coastal eastern India: a preliminary ultrasonographic survey. Trop Gastroenterol 25(2):76–79PubMed

11.

Portillo-Sanchez P, Bril F, Maximos M, Lomonaco R, Biernacki D, Orsak B, Subbarayan S, Webb A, Hecht J, Cusi K (2015) High prevalence of nonalcoholic fatty liver disease in patients with type 2 diabetes mellitus and normal plasma aminotransferase levels. J Clin Endocrinol Metab 100(6):2231–2238. https://doi.org/10.1210/jc.2015-1966CrossRefPubMedPubMedCentral

12.

Perticone F, Sciacqua A, Maio R, Perticone M, Maas R, Boger RH, Tripepi G, Sesti G, Zoccali C (2005) Asymmetric dimethylarginine, L‑arginine, and endothelial dysfunction in essential hypertension. J Am Coll Cardiol 46(3):518–523. https://doi.org/10.1016/j.jacc.2005.04.040CrossRefPubMed

13.

Rijzewijk LJ, Jonker JT, van der Meer RW, Lubberink M, de Jong HW, Romijn JA, Bax JJ, de Roos A, Heine RJ, Twisk JW, Windhorst AD, Lammertsma AA, Smit JW, Diamant M, Lamb HJ (2010) Effects of hepatic triglyceride content on myocardial metabolism in type 2 diabetes. J Am Coll Cardiol 56(3):225–233. https://doi.org/10.1016/j.jacc.2010.02.049CrossRefPubMed

14.

Ganji SH, Kashyap ML, Kamanna VS (2015) Niacin inhibits fat accumulation, oxidative stress, and inflammatory cytokine IL‑8 in cultured hepatocytes: Impact on non-alcoholic fatty liver disease. Metabolism 64(9):982–990. https://doi.org/10.1016/j.metabol.2015.05.002CrossRefPubMed

15.

Cusi K (2009) Nonalcoholic fatty liver disease in type 2 diabetes mellitus. Curr Opin Endocrinol Diabetes Obes 16(2):141–149. https://doi.org/10.1097/MED.0b013e3283293015CrossRefPubMed

16.

Hesselink MKC, Mensink M, Schrauwen P (2007) Lipotoxicity and Mitochondrial Dysfunction in Type 2 Diabetes. Immunol Endocr Metab Agents Med Chem 7(1):3–17CrossRef

17.

Cusi K (2010) The role of adipose tissue and Lipotoxicity in the pathogenesis of type 2 diabetes. Curr Diab Rep 10(4):306–315CrossRefPubMed

18.

Di Sessa A, Umano GR, Miraglia Del Giudice E, Santoro N (2017) From the liver to the heart: cardiac dysfunction in obese children with non-alcoholic fatty liver disease. World J Hepatol 9(2):69–73. https://doi.org/10.4254/wjh.v9.i2.69CrossRefPubMedPubMedCentral

19.

Salamone F, Bugianesi E (2010) Nonalcoholic fatty liver disease: the hepatic trigger of the metabolic syndrome. J Hepatol 53(6):1146–1147. https://doi.org/10.1016/j.jhep.2010.06.013CrossRefPubMed

20.

Kankaanpaa M, Lehto HR, Parkka JP, Komu M, Viljanen A, Ferrannini E, Knuuti J, Nuutila P, Parkkola R, Iozzo P (2006) Myocardial triglyceride content and epicardial fat mass in human obesity: relationship to left ventricular function and serum free fatty acid levels. J Clin Endocrinol Metab 91(11):4689–4695. https://doi.org/10.1210/jc.2006-0584CrossRefPubMed

21.

Boden G (2011) Obesity, insulin resistance and free fatty acids. Curr Opin Endocrinol Diabetes Obes 18(2):139–143. https://doi.org/10.1097/MED.0b013e3283444b09CrossRefPubMedPubMedCentral

22.

Lopaschuk GD, Folmes CDL, Stanley WC (2007) Cardiac energy metabolism in obesity. Circ Res 101(4):335CrossRefPubMed

23.

Muoio D, Neufer PD (2012) Lipid-induced mitochondrial stress and insulin action in muscle. Cell Metab 15(5):595–605CrossRefPubMedPubMedCentral

24.

Ussher JR (2014) The role of cardiac lipotoxicity in the pathogenesis of diabetic cardiomyopathy. Expert Rev Cardiovasc Ther 12(3):345–358CrossRefPubMed

25.

Jaswal JS, Ussher JR, Lopaschuk GD (2009) Myocardial fatty acid utilization as a determinant of cardiac efficiency and function. Clin Lipidol 4(3):379–389. https://doi.org/10.2217/clp.09.18CrossRef

26.

Drosatos K, Schulze PC (2013) Cardiac lipotoxicity: molecular pathways and therapeutic implications. Curr Heart Fail Rep 10(2):109–121. https://doi.org/10.1007/s11897-013-0133-0CrossRefPubMedPubMedCentral

27.

Choi SS, Diehl AM (2008) Hepatic triglyceride synthesis and nonalcoholic fatty liver disease. Curr Opin Lipidol 19(3):295–300. https://doi.org/10.1097/MOL.0b013e3282ff5e55CrossRefPubMed

28.

Marra F, Gastaldelli A, Svegliati Baroni G, Tell G, Tiribelli C (2008) Molecular basis and mechanisms of progression of non-alcoholic steatohepatitis. Trends Mol Med 14(2):72–81. https://doi.org/10.1016/j.molmed.2007.12.003CrossRefPubMed

29.

Mantovani A, Ballestri S, Lonardo A, Targher G (2016) Cardiovascular disease and myocardial abnormalities in nonalcoholic fatty liver disease. Dig Dis Sci 61(5):1246–1267. https://doi.org/10.1007/s10620-016-4040-6CrossRefPubMed

30.

Donnelly KL, Smith CI, Schwarzenberg SJ, Jessurun J, Boldt MD, Parks EJ (2005) Sources of fatty acids stored in liver and secreted via lipoproteins in patients with nonalcoholic fatty liver disease. J Clin Invest 115(5):1343–1351. https://doi.org/10.1172/JCI23621CrossRefPubMedPubMedCentral

31.

Wong WS, Wong LH, Yeung KW, Lau KT, Chan KM, Chim ML, Abrigo JM, Chan SM, Woo J, Tse YK (2015) Incidence of non-alcoholic fatty liver disease in Hong Kong: A population study with paired proton-magnetic resonance spectroscopy. J Hepatol 62(1):182–189CrossRefPubMed

32.

Salvatore P, Christiano A, Daniela C, Calogero C, Vito DM, Daniela C, Antonino T, Giulio M, Antonio P, Giuseppe L (2015) Epicardial fat, cardiac geometry and cardiac function in patients with non-alcoholic fatty liver disease: association with the severity of liver disease. J Hepatol 62(4):928–933CrossRef

33.

Boudina S, Abel ED (2007) Diabetic cardiomyopathy revisited. Circulation 115(25):3213–3223. https://doi.org/10.1161/CIRCULATIONAHA.106.679597CrossRefPubMed

34.

Marra F (2008) Nuclear factor-kappaB inhibition and non-alcoholic steatohepatitis: inflammation as a target for therapy. Gut 57(5):570–572. https://doi.org/10.1136/gut.2007.141986CrossRefPubMed

35.

Videla LA, Tapia G, Rodrigo R, Pettinelli P, Haim D, Santibanez C, Araya AV, Smok G, Csendes A, Gutierrez L, Rojas J, Castillo J, Korn O, Maluenda F, Diaz JC, Rencoret G, Poniachik J (2009) Liver NF-kappaB and AP‑1 DNA binding in obese patients. Obesity (Silver Spring) 17(5):973–979. https://doi.org/10.1038/oby.2008.601CrossRef

36.

Anstee QM, Targher G, Day CP (2013) Progression of NAFLD to diabetes mellitus, cardiovascular disease or cirrhosis. Nat Rev Gastroenterol Hepatol 10(6):330–344. https://doi.org/10.1038/nrgastro.2013.41CrossRefPubMed

37.

Targher G, Byrne CD (2013) Clinical review: nonalcoholic fatty liver disease: a novel cardiometabolic risk factor for type 2 diabetes and its complications. J Clin Endocrinol Metab 98(2):483–495. https://doi.org/10.1210/jc.2012-3093CrossRefPubMed

38.

Mangi MA, Rehman H, Minhas AM, Rafique M, Bansal V, Constantin J (2017) Non-alcoholic fatty liver disease association with cardiac arrhythmias. Cureus 9(4):e1165. https://doi.org/10.7759/cureus.1165CrossRefPubMedPubMedCentral

39.

Mantovani A (2017) Nonalcoholic fatty liver disease (NAFLD) and risk of cardiac arrhythmias: a new aspect of the liver-heart axis. J Clin Transl Hepatol 5(2):134–141. https://doi.org/10.14218/JCTH.2017.00005CrossRefPubMedPubMedCentral

40.

Sinner MF, Wang N, Fox CS, Fontes JD, Rienstra M, Magnani JW, Vasan RS, Calderwood AH, Pencina M, Sullivan LM, Ellinor PT, Benjamin EJ (2013) Relation of circulating liver transaminase concentrations to risk of new-onset atrial fibrillation. Am J Cardiol 111(2):219–224. https://doi.org/10.1016/j.amjcard.2012.09.021CrossRefPubMed

41.

Alonso A, Misialek JR, Amiin MA, Hoogeveen RC, Chen LY, Agarwal SK, Loehr LR, Soliman EZ, Selvin E (2014) Circulating levels of liver enzymes and incidence of atrial fibrillation: the Atherosclerosis Risk in Communities cohort. Heart 100(19):1511–1516. https://doi.org/10.1136/heartjnl-2014-305756CrossRefPubMed

42.

Targher G, Mantovani A, Pichiri I, Rigolon R, Dauriz M, Zoppini G, Morani G, Vassanelli C, Bonora E (2013) Non-alcoholic fatty liver disease is associated with an increased prevalence of atrial fibrillation in hospitalized patients with type 2 diabetes. Clin Sci 125(6):301–309. https://doi.org/10.1042/CS20130036CrossRef

43.

Targher G, Valbusa F, Bonapace S, Bertolini L, Zenari L, Rodella S, Zoppini G, Mantovani W, Barbieri E, Byrne CD (2013) Non-alcoholic fatty liver disease is associated with an increased incidence of atrial fibrillation in patients with type 2 diabetes. PLoS ONE 8(2):e57183. https://doi.org/10.1371/journal.pone.0057183CrossRefPubMedPubMedCentral

44.

Karajamaki AJ, Patsi OP, Savolainen M, Kesaniemi YA, Huikuri H, Ukkola O (2015) Non-alcoholic fatty liver disease as a predictor of atrial fibrillation in middle-aged population (OPERA study). PLoS ONE 10(11):e142937. https://doi.org/10.1371/journal.pone.0142937CrossRefPubMedPubMedCentral

45.

Zhang Y, Li P, Miao M, Liu Y, Pan Y, Xu L, Zhu Z, Xu C, Xu L (2018) Nonalcoholic fatty liver disease is associated with increased atrial fibrillation risk in an elderly Chinese population: a cross-sectional study. Biomed Res Int 2018:5628749. https://doi.org/10.1155/2018/5628749CrossRefPubMedPubMedCentral

46.

Iscen S (2013) RBBB is associated with an increased risk of NAFLD in young healthy individuals. Int J Cardiol 168(4):4056–4057. https://doi.org/10.1016/j.ijcard.2013.07.035CrossRefPubMed

47.

Mangi MA, Minhas AM, Rehman H, Pathan F, Liang H, Beidas S (2017) Association of non-alcoholic fatty liver disease with conduction defects on electrocardiogram. Cureus 9(3):e1107. https://doi.org/10.7759/cureus.1107CrossRefPubMedPubMedCentral

48.

Mantovani A, Rigolon R, Pichiri I, Bonapace S, Morani G, Zoppini G, Bonora E, Targher G (2017) Nonalcoholic fatty liver disease is associated with an increased risk of heart block in hospitalized patients with type 2 diabetes mellitus. PLoS ONE 12(10):e185459. https://doi.org/10.1371/journal.pone.0185459CrossRefPubMedPubMedCentral

49.

Hung CS, Tseng PH, Tu CH, Chen CC, Liao WC, Lee YC, Chiu HM, Lin HJ, Ho YL, Yang WS, Wu MS, Chen MF (2015) Nonalcoholic fatty liver disease is associated with QT prolongation in the general population. J Am Heart Assoc. https://doi.org/10.1161/JAHA.115.001820CrossRefPubMedPubMedCentral

50.

Targher G, Valbusa F, Bonapace S, Bertolini L, Zenari L, Pichiri I, Mantovani A, Zoppini G, Bonora E, Barbieri E, Byrne CD (2014) Association of nonalcoholic fatty liver disease with QTc interval in patients with type 2 diabetes. Nutr Metab Cardiovasc Dis 24(6):663–669. https://doi.org/10.1016/j.numecd.2014.01.005CrossRefPubMed

51.

Mantovani A, Rigamonti A, Bonapace S, Bolzan B, Pernigo M, Morani G, Franceschini L, Bergamini C, Bertolini L, Valbusa F, Rigolon R, Pichiri I, Zoppini G, Bonora E, Violi F, Targher G (2016) Nonalcoholic fatty liver disease is associated with ventricular arrhythmias in patients with type 2 diabetes referred for clinically indicated 24-hour Holter monitoring. Diabetes Care 39(8):1416–1423. https://doi.org/10.2337/dc16-0091CrossRefPubMed

52.

Goland S, Shimoni S, Zornitzki T, Knobler H, Azoulai O, Lutaty G, Melzer E, Orr A, Caspi A, Malnick S (2006) Cardiac abnormalities as a new manifestation of nonalcoholic fatty liver disease: echocardiographic and tissue Doppler imaging assessment. J Clin Gastroenterol 40(10):949–955. https://doi.org/10.1097/01.mcg.0000225668.53673.e6CrossRefPubMed

53.

Fotbolcu H, Yakar T, Duman D, Karaahmet T, Tigen K, Cevik C, Kurtoglu U, Dindar I (2010) Impairment of the left ventricular systolic and diastolic function in patients with non-alcoholic fatty liver disease. Cardiol J 17(5):457–463PubMed

54.

Karabay CY, Kocabay G, Kalayci A, Colak Y, Oduncu V, Akgun T, Kalkan S, Guler A, Kirma C (2014) Impaired left ventricular mechanics in nonalcoholic fatty liver disease: a speckle-tracking echocardiography study. Eur J Gastroenterol Hepatol 26(3):325–331. https://doi.org/10.1097/MEG.0000000000000008CrossRefPubMed

55.

Trovato FM, Martines GF, Catalano D, Musumeci G, Pirri C, Trovato GM (2016) Echocardiography and NAFLD (non-alcoholic fatty liver disease). Int J Cardiol 221:275–279. https://doi.org/10.1016/j.ijcard.2016.06.180CrossRefPubMed

56.

VanWagner LB, Wilcox JE, Colangelo LA, Lloyd-Jones DM, Carr JJ, Lima JA, Lewis CE, Rinella ME, Shah SJ (2015) Association of nonalcoholic fatty liver disease with subclinical myocardial remodeling and dysfunction: a population-based study. Hepatology 62(3):773–783. https://doi.org/10.1002/hep.27869CrossRefPubMed

57.

Zamirian MM, Samiee EM, Moaref AM, Abtahi FM, Tahamtan MM (2018) Assessment of subclinical myocardial changes in non-alcoholic fatty liver disease: a case-control study using speckle tracking echocardiography. Iran J Med Sci 43(5):466–472

58.

Sert A, Aypar E, Pirgon O, Yilmaz H, Odabas D, Tolu I (2013) Left ventricular function by echocardiography, tissue Doppler imaging, and carotid intima-media thickness in obese adolescents with nonalcoholic fatty liver disease. Am J Cardiol 112(3):436–443. https://doi.org/10.1016/j.amjcard.2013.03.056CrossRefPubMed

59.

Wang Q, Ma W, Xia J (2018) Nonalcoholic fatty liver is associated with further left ventricular abnormalities in patients with type 2 diabetes mellitus: a 3‑dimensional speckle-tracking study. J Ultrasound Med 37(8):1899–1911. https://doi.org/10.1002/jum.14536CrossRefPubMed

60.

Lee H, Kim G, Choi YJ, Huh BW, Lee BW, Kang ES, Cha BS, Lee EJ, Lee YH, Huh KB (2019) Association between non-alcoholic steatohepatitis and left ventricular diastolic dysfunction in type 2 diabetes mellitus. Diabetes Metab J. https://doi.org/10.4093/dmj.2019.0001CrossRefPubMedPubMedCentral

61.

Mantovani A, Zoppini G, Targher G, Golia G, Bonora E (2012) Non-alcoholic fatty liver disease is independently associated with left ventricular hypertrophy in hypertensive Type 2 diabetic individuals. J Endocrinol Invest 35(2):215–218. https://doi.org/10.1007/bf03345421CrossRefPubMed

62.

Pacifico L, Di Martino M, De Merulis A, Bezzi M, Osborn JF, Catalano C, Chiesa C (2014) Left ventricular dysfunction in obese children and adolescents with nonalcoholic fatty liver disease. Hepatology 59(2):461–470. https://doi.org/10.1002/hep.26610CrossRefPubMed

63.

Alp H, Karaarslan S, Selver Eklioglu B, Atabek ME, Altin H, Baysal T (2013) Association between nonalcoholic fatty liver disease and cardiovascular risk in obese children and adolescents. Can J Cardiol 29(9):1118–1125. https://doi.org/10.1016/j.cjcaCrossRefPubMed

64.

Kocabay G, Karabay CY, Colak Y, Oduncu V, Kalayci A, Akgun T, Guler A, Kirma C (2014) Left atrial deformation parameters in patients with non-alcoholic fatty liver disease: a 2D speckle tracking imaging study. Clin Sci 126(4):297–304. https://doi.org/10.1042/CS20130298CrossRef

65.

Bonapace S, Perseghin G, Molon G, Canali G, Bertolini L, Zoppini G, Barbieri E, Targher G (2012) Nonalcoholic fatty liver disease is associated with left ventricular diastolic dysfunction in patients with type 2 diabetes. Diabetes Care 35(2):389–395. https://doi.org/10.2337/dc11-1820CrossRefPubMedPubMedCentral

66.

Mantovani A, Pernigo M, Bergamini C, Bonapace S, Lipari P, Pichiri I, Bertolini L, Valbusa F, Barbieri E, Zoppini G, Bonora E, Targher G (2015) Nonalcoholic fatty liver disease is independently associated with early left ventricular diastolic dysfunction in patients with type 2 diabetes. PLoS ONE 10(8):e135329. https://doi.org/10.1371/journal.pone.0135329CrossRefPubMedPubMedCentral

67.

Fallo F, Dalla Pozza A, Sonino N, Lupia M, Tona F, Federspil G, Ermani M, Catena C, Soardo G, Di Piazza L, Bernardi S, Bertolotto M, Pinamonti B, Fabris B, Sechi LA (2009) Non-alcoholic fatty liver disease is associated with left ventricular diastolic dysfunction in essential hypertension. Nutr Metab Cardiovasc Dis 19(9):646–653. https://doi.org/10.1016/j.numecd.2008.12.007CrossRefPubMed

68.

Singh GK, Vitola BE, Holland MR, Sekarski T, Patterson BW, Magkos F, Klein S (2013) Alterations in ventricular structure and function in obese adolescents with nonalcoholic fatty liver disease. J Pediatr 162(6):1160–1168, 1168.e1. https://doi.org/10.1016/j.jpeds.2012.11.024CrossRefPubMed

69.

Sunbul M, Kivrak T, Durmus E, Akin H, Aydin Y, Ergelen R, Yilmaz Y, Agirbasli M (2015) Nonalcoholic steatohepatitis score is an independent predictor of right ventricular dysfunction in patients with nonalcoholic fatty liver disease. Cardiovasc Ther 33(5):294–299. https://doi.org/10.1111/1755-5922.12145CrossRefPubMed

70.

Bekler A, Gazi E, Erbag G, Binnetoglu E, Barutcu A, Sen H, Temiz A, Altun B (2015) Right ventricular function and its relationship with grade of hepatosteatosis in non-alcoholic fatty liver disease. Cardiovasc J Afr 26(3):109–113. https://doi.org/10.5830/CVJA-2014-068CrossRefPubMedPubMedCentral

71.

Budoff MJ, Achenbach S, Blumenthal RS, Carr JJ, Goldin JG, Greenland P, Guerci AD, Lima JA, Rader DJ, Rubin GD, Shaw LJ, Wiegers SE (2006) Assessment of coronary artery disease by cardiac computed tomography: a scientific statement from the American Heart Association Committee on Cardiovascular Imaging and Intervention, Council on Cardiovascular Radiology and Intervention, and Committee on Cardiac Imaging, Council on Clinical Cardiology. Circulation 114(16):1761–1791. https://doi.org/10.1161/circulationaha.106.178458CrossRefPubMed

72.

Chen CH, Nien CK, Yang CC, Yeh YH (2010) Association between nonalcoholic fatty liver disease and coronary artery calcification. Dig Dis Sci 55(6):1752–1760. https://doi.org/10.1007/s10620-009-0935-9CrossRefPubMed

73.

Chhabra R, O’Keefe JH, Patil H, O’Keefe E, Thompson RC, Ansari S, Kennedy KF, Lee LW, Helzberg JH (2013) Association of coronary artery calcification with hepatic steatosis in asymptomatic individuals. Mayo Clin Proc 88(11):1259–1265. https://doi.org/10.1016/j.mayocp.2013.06.025CrossRefPubMed

74.

Sung KC, Wild SH, Kwag HJ, Byrne CD (2012) Fatty liver, insulin resistance, and features of metabolic syndrome: relationships with coronary artery calcium in 10,153 people. Diabetes Care 35(11):2359–2364. https://doi.org/10.2337/dc12-0515CrossRefPubMedPubMedCentral

75.

Kim D, Choi SY, Park EH, Lee W, Kang JH, Kim W, Kim YJ, Yoon JH, Jeong SH, Lee DH, Lee HS, Larson J, Therneau TM, Kim WR (2012) Nonalcoholic fatty liver disease is associated with coronary artery calcification. Hepatology 56(2):605–613. https://doi.org/10.1002/hep.25593CrossRefPubMed

76.

Akabame S, Hamaguchi M, Tomiyasu K, Tanaka M, Kobayashi-Takenaka Y, Nakano K, Oda Y, Yoshikawa T (2008) Evaluation of vulnerable coronary plaques and non-alcoholic fatty liver disease (NAFLD) by 64-detector multislice computed tomography (MSCT). Circulation 72(4):618–625CrossRef

77.

Assy N, Djibre A, Farah R, Grosovski M, Marmor A (2010) Presence of coronary plaques in patients with nonalcoholic fatty liver disease. Radiology 254(2):393–400. https://doi.org/10.1148/radiol.09090769CrossRefPubMed

78.

Kang MK, Kang BH, Kim JH (2015) Nonalcoholic fatty liver disease is associated with the presence and morphology of subclinical coronary atherosclerosis. Yonsei Med J 56(5):1288–1295. https://doi.org/10.3349/ymj.2015.56.5.1288CrossRefPubMedPubMedCentral

79.

Choi DH, Lee SJ, Kang CD, Park MO, Choi DW, Kim TS, Lee W, Cho BR, Kim YH, Lee BK, Ryu DR, Lee JW (2013) Nonalcoholic fatty liver disease is associated with coronary artery disease in Koreans. World J Gastroenterol 19(38):6453–6457. https://doi.org/10.3748/wjg.v19.i38.6453CrossRefPubMedPubMedCentral

80.

Ten Hove M, Neubauer S (2007) MR spectroscopy in heart failure—clinical and experimental findings. Heart Fail Rev 12(1):48–57. https://doi.org/10.1007/s10741-007-9003-8CrossRefPubMed

81.

Graner M, Nyman K, Siren R, Pentikainen MO, Lundbom J, Hakkarainen A, Lauerma K, Lundbom N, Nieminen MS, Taskinen MR (2015) Ectopic fat depots and left ventricular function in nondiabetic men with nonalcoholic fatty liver disease. Circ Cardiovasc Imaging. https://doi.org/10.1161/circimaging.114.001979CrossRefPubMed

82.

Hallsworth K, Hollingsworth KG, Thoma C, Jakovljevic D, MacGowan GA, Anstee QM, Taylor R, Day CP, Trenell MI (2013) Cardiac structure and function are altered in adults with non-alcoholic fatty liver disease. J Hepatol 58(4):757–762. https://doi.org/10.1016/j.jhep.2012.11.015CrossRefPubMed

83.

Crilley JG, Boehm EA, Blair E, Rajagopalan B, Blamire AM, Styles P, McKenna WJ, Ostman-Smith I, Clarke K, Watkins H (2003) Hypertrophic cardiomyopathy due to sarcomeric gene mutations is characterized by impaired energy metabolism irrespective of the degree of hypertrophy. J Am Coll Cardiol 41(10):1776–1782CrossRefPubMed

84.

Nakamori S, Onishi K, Nakajima H, Yoon YE, Nagata M, Kurita T, Yamada T, Kitagawa K, Dohi K, Nakamura M, Sakuma H, Ito M (2012) Impaired myocardial perfusion reserve in patients with fatty liver disease assessed by quantitative myocardial perfusion magnetic resonance imaging. Circ J 76(9):2234–2240. https://doi.org/10.1253/circj.CJ-11-1487CrossRefPubMed

85.

Lee YH, Kim KJ, Yoo ME, Kim G, Yoon HJ, Jo K, Youn JC, Yun M, Park JY, Shim CY, Lee BW, Kang SM, Ha JW, Cha BS, Kang ES (2018) Association of non-alcoholic steatohepatitis with subclinical myocardial dysfunction in non-cirrhotic patients. J Hepatol 68(4):764–772. https://doi.org/10.1016/j.jhep.2017.11.023CrossRefPubMed

86.

Tang K, Lin J, Ji X, Lin T, Sun D, Zheng X, Wang L (2019) Non-alcoholic fatty liver disease with reduced myocardial FDG uptake is associated with coronary atherosclerosis. J Nucl Cardiol. https://doi.org/10.1007/s12350-019-01736-6CrossRefPubMed

87.

Tang K, Zheng X, Lin J, Zheng M, Lin H, Li T, Wang L (2018) Association between non-alcoholic fatty liver disease and myocardial glucose uptake measured by (18)F-fluorodeoxyglucose positron emission tomography. J Nucl Cardiol. https://doi.org/10.1007/s12350-018-1446-xCrossRefPubMed

Titel: Cardiac abnormalities in patients with nonalcoholic fatty liver disease
Insights from auxiliary examinations
verfasst von: Yu Dong, MD
Guangsen Li, PhD
Publikationsdatum: 19.09.2019
Verlag: Springer Medizin
Erschienen in: Herz / Ausgabe 2/2021
Print ISSN: 0340-9937
Elektronische ISSN: 1615-6692
DOI: https://doi.org/10.1007/s00059-019-04855-5

Update Kardiologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Die Highlights vom Kongress des American College of Cardiology 2024

Springer Medizin

Cardiac abnormalities in patients with nonalcoholic fatty liver disease

Insights from auxiliary examinations

Abstract

Neu im Fachgebiet Kardiologie

„Übersichtlicher Wegweiser“: Lauterbachs umstrittener Klinik-Atlas ist online

„Jeder Fall von plötzlichem Tod muss obduziert werden!“

Hirnblutung unter DOAK und VKA ähnlich bedrohlich

Schlechtere Vorhofflimmern-Prognose bei kleinem linken Ventrikel

Update Kardiologie

Die Highlights vom Kongress des American College of Cardiology 2024

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 2/2021

Herz-Kreislauf-Erkrankungen und COVID-19

Dynamic thiol/disulphide homeostasis in patients with hypertrophic cardiomyopathy

Neglected cardiovascular diseases and their significance in the Global North

COVID-19-Pandemie

Relationship between neointimal strut bridge and jailed side-branch ostial area

Gender and career in cardiology—a cross-sectional study

Neu im Fachgebiet Kardiologie

„Übersichtlicher Wegweiser“: Lauterbachs umstrittener Klinik-Atlas ist online

„Jeder Fall von plötzlichem Tod muss obduziert werden!“

Hirnblutung unter DOAK und VKA ähnlich bedrohlich

Schlechtere Vorhofflimmern-Prognose bei kleinem linken Ventrikel

Update Kardiologie